Vuong Trieu, PhD
Founder of IgDraSol and Biomiga Diagnostics. Led the development of Abraxane, nab-docetaxel, nab-rapamycin, nab- 17-AAG, nab-IDN5404. Repositioned Genexol-PM from Korea into a viable product for US market as Abraxane equivalent and as drug-device combination. Conducted a successful EOP2 meeting within 7 months of acquiring the asset.
Abraxis Biosciences,(ABI), Celgene, AME (Eli Lilly), Genetic Therapy Inc. (Novartis), IgDraSol, Sorrento Therapeutics
Chulho Park, PhD
Recognized pharmaceutical leader in Korea with strong business development background. Leader in the field of mAb engineering. CEO and Founder of MabPrex. Led the pharmaceutical development of therapeutic antibodies as well as small molecule drugs. President of Pharmaceutical Development at Igdrasol. Led the CMC deveopment at IgDraSol bringing manufacturing of the drug product to US FDA standard.
Eli Lilly, AME, aTyr, MabPrex, IgDraSol